Beta-lactamase produced by Bacteroides fragilis
could protect from antibiotics group A beta-hemolytic streptococci (GABHS), penicillin-susceptible pathogens frequently isolated from acute tonsillitis in children. To test this hypothesis we determined the minimal bactericidal concentration (MBC) to penicillin and cephalothin of GABHS alone and in mixed culture with eleven beta-lactamase-producing strains of B. fragilis. B. fragilis
strains with MBC values ≤ 32 μg/mlto penicillin and ≤64 μg/ml to cephalothin did not provide any protection for GABHS. However, strains with MBC ≥ 128 μg/ml to penicillin and ≥ 256 μg/ml to cephalothin provided protection by increasing the MBC of GABHS at least 8,534 times for penicillin and 2,048 times for cephalothin. This phenomenon was most marked in 5% CO2
. B. fragilis
provided no protection against clindamycin. These results may explain the inability of penicillin therapy to completely eradicate GABHS from cases of recurrently infected tonsils.
Itzhak Brook, MD, Naval Medical Research Institute, National Naval Medical Center, Bethesda, MD 20814 (USA)
Published online: September 08, 2009
Number of Print Pages : 6
Chemotherapy (International Journal of Experimental and Clinical Chemotherapy)
Vol. 29, No. 1, Year 1983 (Cover Date: 1983)
Journal Editor: Sörgel F. (Nürnberg-Heroldsberg)
ISSN: 0009-3157 (Print), eISSN: 1421-9794 (Online)
For additional information: http://www.karger.com/CHE
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.